These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29357929)

  • 21. Optimizing neoadjuvant therapy for rectal cancer with oxaliplatin.
    Martin LK; Bekaii-Saab T
    J Natl Compr Canc Netw; 2013 Mar; 11(3):298-307; quiz 307. PubMed ID: 23486456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-arm, phase II study of intra-arterial chemotherapy plus total neoadjuvant therapy to optimise complete response in distal rectal cancer: a study protocol.
    Huang W; Huang P; Guo H; Huang Z; Wei M; Guo J; Lin C; Li Y; Luo B; Lin J; Wang L
    BMJ Open; 2023 Oct; 13(10):e075023. PubMed ID: 37798027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of age on efficacy of postoperative oxaliplatin-based chemotherapy in patients with rectal cancer after neoadjuvant chemoradiotherapy.
    Huang XZ; Gao P; Song YX; Sun JX; Chen XW; Zhao JH; Ma B; Wang J; Wang ZN
    Oncotarget; 2016 Apr; 7(15):19643-53. PubMed ID: 26910371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial.
    Hofheinz RD; Arnold D; Fokas E; Kaufmann M; Hothorn T; Folprecht G; Fietkau R; Hohenberger W; Ghadimi M; Liersch T; Grabenbauer GG; Sauer R; Rödel C; Graeven U;
    Ann Oncol; 2018 Aug; 29(8):1793-1799. PubMed ID: 29873684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pilot study of intense neoadjuvant chemoradiotherapy for locally advanced rectal cancer: retrospective review of a phase II study.
    Xu BH; Chi P; Guo JH; Guan GX; Tang TL; Yang YH; Chen MQ; Song JY; Feng CY
    Tumori; 2014; 100(2):149-57. PubMed ID: 24852858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
    Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W
    Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma.
    Margalit O; Mamtani R; Kopetz S; Yang YX; Lawrence YR; Abu-Gazala S; Reiss KA; Golan T; Halpern N; Aderka D; Giantonio B; Shacham-Shmueli E; Boursi B
    Oncologist; 2019 Aug; 24(8):e671-e676. PubMed ID: 30696723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
    Iveson T; Boyd KA; Kerr RS; Robles-Zurita J; Saunders MP; Briggs AH; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Pearson S; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan H; Paul J
    Health Technol Assess; 2019 Dec; 23(64):1-88. PubMed ID: 31852579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
    Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
    Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxaliplatin-based adjuvant chemotherapy rather than fluorouracil-based chemotherapy in rectal cancer is more efficient to decrease distant metastasis and increase survival after preoperative chemoradiotherapy and surgery: a meta-analysis.
    Song JH; Lee JH; Kim SH; Um JW;
    Int J Colorectal Dis; 2022 Mar; 37(3):649-656. PubMed ID: 35050402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcatheter rectal arterial chemoembolization with oxaliplatin plus S-1 concurrent chemoradiotherapy can improve the pathological remission rate in locally advanced rectal cancer: a comparative study.
    Yang B; Shan J; Feng Y; Dai N; Li M; Chen C; He S; Wang G; Xiao H; Li C; Wang D
    Radiat Oncol; 2020 May; 15(1):94. PubMed ID: 32375814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathological Complete Response Following Different Neoadjuvant Treatment Strategies for Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis.
    Hoendervangers S; Burbach JPM; Lacle MM; Koopman M; van Grevenstein WMU; Intven MPW; Verkooijen HM
    Ann Surg Oncol; 2020 Oct; 27(11):4319-4336. PubMed ID: 32524461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy and safety of total neoadjuvant therapy versus neoadjuvant chemoradiotherapy in the treatment of locally advanced rectal cancer: a meta-analysis].
    Zhang YQ; Sun KG; Lu JY; Ma J; Yao N; Qin ZH; Yao YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jun; 25(6):531-538. PubMed ID: 35754218
    [No Abstract]   [Full Text] [Related]  

  • 35. Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer.
    Araujo-Mino EP; Patt YZ; Murray-Krezan C; Hanson JA; Bansal P; Liem BJ; Rajput A; Fekrazad MH; Heywood G; Lee FC
    Oncologist; 2018 Jan; 23(1):2-e5. PubMed ID: 29158365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance).
    Schrag D; Weiser M; Saltz L; Mamon H; Gollub M; Basch E; Venook A; Shi Q
    Clin Trials; 2019 Apr; 16(2):165-175. PubMed ID: 30688523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study.
    Okuyama T; Sameshima S; Takeshita E; Yoshioka R; Yamagata Y; Ono Y; Tagaya N; Noie T; Oya M
    World J Surg Oncol; 2018 Jun; 16(1):105. PubMed ID: 29871650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Local versus radical surgery for early rectal cancer with or without neoadjuvant or adjuvant therapy.
    Motamedi MAK; Mak NT; Brown CJ; Raval MJ; Karimuddin AA; Giustini D; Phang PT
    Cochrane Database Syst Rev; 2023 Jun; 6(6):CD002198. PubMed ID: 37310167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
    Allegra CJ; Yothers G; O'Connell MJ; Beart RW; Wozniak TF; Pitot HC; Shields AF; Landry JC; Ryan DP; Arora A; Evans LS; Bahary N; Soori G; Eakle JF; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Sharif S; Roh MS; Wolmark N
    J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26374429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The neoadjuvant treatment of rectal cancer: a review.
    Nussbaum N; Altomare I
    Curr Oncol Rep; 2015 Mar; 17(3):434. PubMed ID: 25691086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.